Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:19 PM
Ignite Modification Date:
2025-12-24 @ 11:19 PM
NCT ID:
NCT04893356
Eligibility Criteria:
Inclusion Criteria:
\- Patients with a histological diagnosis of metastatic LMS and SFT from 2010 to 2020, previously treated with dacarbazine alone or with anthracyclines as first line of chemotherapy.
Exclusion Criteria:
* Patients with histological diagnosis of metastatic LMS and SFT, received before 2010.
* Patients with histological diagnosis of metastatic LMS and SFT from 2010 to 2020, never treated with dacarbazine
* Patients with a histological diagnosis of metastatic LMS and SFT from 2010 to 2020, previously treated with dacarbazine alone or with anthracyclines as the first line of chemotherapy, of which, however, there is no tissue sample
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT04893356
Study Brief:
Protocol Section:
NCT04893356